液体活检在上皮性卵巢癌诊治中的应用

doi:10.3760/cma.j.issn.1673422X.2018.02.015

摘要/Abstract

摘要： 液体活检已在恶性肿瘤研究领域取得重大进展，循环肿瘤细胞、循环肿瘤DNA、外泌体等可作为生物标志物用于上皮性卵巢癌的检测、动态监测病情变化、判断患者预后、评估化疗药物耐药性等，可为患者制定个体化的治疗方案提供依据，实现上皮性卵巢癌的精准医疗。

关键词: 卵巢肿瘤, 液体活检

Abstract: Liquid biopsies have made a great progress in malignant tumors research. Circulating tumor cells, circulating tumor DNA and exosomes can be regarded as biomarkers to be applied in diagnosis of epithelial ovarian cancer, monitoring progress dynamically, estimating prognosis and drug resistance in chemotherapy, which can help doctors provide patients with individual treatment to realize precision medicine in epithelial ovarian cancer.

Key words: Ovarian neoplasms, Liquid biopsy

唐慧芸, 莫小雨, 白莉平, 郑艾. 液体活检在上皮性卵巢癌诊治中的应用[J]. 国际肿瘤学杂志, 2018, 45(2): 122-125.

TANG Hui-Yun, MO Xiao-Yu, BAI Li-Ping, ZHENG Ai. Application of liquid biopsies in diagnosis and treatment of epithelial ovarian cancer[J]. Journal of International Oncology, 2018, 45(2): 122-125.

参考文献

［1］ Zhou Y, Bian B, Yuan X, et al. Prognostic value of circulating tumor cells in ovarian cancer: a metaanalysis［J］. PLoS One, 2015, 10(6): e0130873. DOI: 10.1371/journal.pone.0130873. ［2］ Khosravi F, Trainor PJ, Lambert C, et al. Static microarray isolation, dynamic time series classification, capture and enumeration of spiked breast cancer cells in blood: the nanotubeCTC chip［J］. Nanotechnology, 2016, 27(44): 44LT03. DOI: 10.1088/09574484/27/44/44LT03. ［3］ Masuda T, Hayashi N, Iguchi T, et al. Clinical and biological significance of circulating tumor cells in cancer［J］. Mol Oncol, 2016, 10(3): 408417. DOI: 10.1016/j.molonc.2016.01.010. ［4］ Gu Y, Ju C, Li Y, et al. Detection of circulating tumor cells in prostate cancer based on carboxylated graphene oxide modified light addressable potentiometric sensor［J］. Biosens Bioelectron, 2015, 66: 2431. DOI: 10.1016/j.bios.2014.10.070. ［5］ Bu J, Kim YJ, Kang YT, et al. Polyester fabric sheet layers functionalized with graphene oxide for sensitive isolation of circulating tumor cells［J］. Biomaterials, 2017, 125: 111. DOI: 10.1016/j.biomaterials.2017.02.009. ［6］ Obermayr E, SanchezCabo F, Tea MK, et al. Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients［J］. BMC Cancer, 2010, 10: 666. DOI: 10.1186/1471240710666. ［7］ Kolostova K, Pinkas M, Jakabova A, et al. Molecular characterization of circulating tumor cells in ovarian cancer［J］. Am J Cancer Res, 2016, 6(5): 973980. ［8］ RomeroLaorden N, Olmos D, Fehm T, et al. Circulating and disseminated tumor cells in ovarian cancer: a systematic review［J］. Gynecol Oncol, 2014, 133(3): 632639. DOI: 10.1016/j.ygyno.2014.03.016. ［9］ Kolostova K, Matkowski R, Jdryka M, et al. The added value of circulating tumor cells examination in ovarian cancer staging［J］. Am J Cancer Res, 2015, 5(11): 33633375. ［10］ Lee M, Kim EJ, Cho Y, et al. Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer［J］. Gynecol Oncol, 2017, 145(2): 361365. DOI: 10.1016/j.ygyno.2017.02.042. ［11］ Kuhlmann JD, Wimberger P, Bankfalvi A, et al. ERCC1positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance［J］. Clin Chem, 2014, 60(10): 12821289. DOI: 10.1373/clinchem.2014.224808. ［12］ Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer［J］. Clin Chem, 2015, 61(1): 112123. DOI: 10.1373/clinchem.2014.222679. ［13］ Thierry AR, El Messaoudi S, Gahan PB, et al. Origins, structures, and functions of circulating DNA in oncology［J］. Cancer Metastasis Rev, 2016, 35(3): 347376. DOI: 10.1007/s105550169629x. ［14］ Kamat AA, Sood AK, Dang D, et al. Quantification of total plasma cellfree DNA in ovarian cancer using realtime PCR［J］. Ann N Y Acad Sci, 2006, 1075: 230234. DOI: 10.1196/annals.1368.031. ［15］ Zachariah RR, Schmid S, Buerki N, et al. Levels of circulating cellfree nuclear and mitochondrial DNA in benign and malignant ovarian tumors［J］. Obstet Gynecol, 2008, 112(4): 843850. DOI: 10.1097/AOG.0b013e3181867bc0. ［16］ Bianchi DW, Chudova D, Sehnert AJ, et al. Noninvasive prenatal testing and incidental detection of occult maternal malignancies［J］. JAMA, 2015, 314(2): 162169. DOI: 10.1001/jama.2015.7120. ［17］ Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer［J］. CA Cancer J Clin, 2011, 61(3): 183203. DOI: 10.3322/caac.20113. ［18］ Dobrzycka B, Terlikowski SJ, Kinalski M, et al. Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers［J］. Ann Oncol, 2011, 22(5): 11331140. DOI: 10.1093/annonc/mdq584. ［19］ Parkinson CA, Gale D, Piskorz AM, et al. Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed highgrade serous ovarian carcinoma: a retrospective study［J］. PLoS Med, 2016, 13(12): e1002198. DOI: 10.1371/journal.pmed.1002198. ［20］ Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early and latestage human malignancies［J］. Sci Transl Med, 2014, 6(224): 224ra24. DOI: 10.1126/scitranslmed.3007094. ［21］ Kuhlmann JD, Schwarzenbach H, Wimberger P, et al. LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival［J］. BMC Cancer, 2012, 12: 325. DOI: 10.1186/1471240712325. ［22］ Christie EL, Fereday S, Doig K, et al. Reversion of BRCA1/2 germline mutations detected in circulating tumor DNA from patients with highgrade serous ovarian cancer［J］. J Clin Oncol, 2017, 35(12): 12741280. DOI: 10.1200/JCO.2016.70.4627. ［23］ Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis［J］. J Mol Med (Berl), 2013, 91(4): 431437. DOI: 10.1007/s0010901310206. ［24］ Balaj L, Lessard R, Dai L, et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences［J］. Nat Commun, 2011, 2: 180. DOI: 10.1038/ncomms1180. ［25］ Lea J, Sharma R, Yang F, et al. Detection of phosphatidylserinepositive exosomes as a diagnostic marker for ovarian malignancies—a proof of concept study［J］. Oncotarget, 2017, 8(9): 1439514407. DOI: 10.18632/oncotarget.14795. ［26］ Nakamura K, Sawada K, Yoshimura A, et al. Clinical relevance of circulating cellfree microRNAs in ovarian cancer［J］. Mol Cancer, 2016, 15(1): 48. DOI: 10.1186/s1294301605360. ［27］ Miska EA. How microRNAs control cell division, differentiation and death［J］. Curr Opin Genet Dev, 2005, 15(5): 563568. DOI: 10.1016/j.gde.2005.08.005. ［28］ Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer［J］. Cancer Res, 2007, 67(18): 86998707. DOI: 10.1158/00085472.CAN071936. ［29］ Taylor DD, GercelTaylor C. MicroRNA signatures of tumorderived exosomes as diagnostic biomarkers of ovarian cancer［J］. Gynecol Oncol, 2008, 110(1): 1321. DOI: 10.1016/j.ygyno.2008.04.033. ［30］ Au Yeung CL, Co NN, Tsuruga T, et al. Exosomal transfer of stromaderived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1［J］. Nat Commun, 2016, 7: 11150. DOI: 10.1038/ncomms11150. ［31］ Yan X, Yin J, Yao H, et al. Increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer［J］. Cancer Res, 2010, 70(4): 16161624. DOI: 10.1158/00085472.CAN093215.

[1]	龚艳, 陈洪雷. 微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.
[2]	安荣, 刘美华, 王佩晨, 王晓慧. Nrf2在卵巢癌中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(8): 493-497.
[3]	李晨曦, 赵宏伟. 二次肿瘤细胞减灭术治疗初始减瘤手术不满意铂敏感复发性卵巢癌的预后及影响因素分析[J]. 国际肿瘤学杂志, 2023, 50(6): 342-347.
[4]	杨丽蓉, 王羽丰. 预测浆液性卵巢癌术后复发远处转移风险机器学习模型的构建[J]. 国际肿瘤学杂志, 2023, 50(4): 220-226.
[5]	庄伟涛, 乔贵宾. 基于表观遗传标志的液体活检在实体瘤诊疗中的研究与应用[J]. 国际肿瘤学杂志, 2021, 48(6): 358-361.
[6]	李晨曦, 赵宏伟. PARP抑制剂治疗铂耐药卵巢癌的研究进展[J]. 国际肿瘤学杂志, 2021, 48(3): 180-183.
[7]	李哲丰, 李洁, 赵晓婷, 岳文涛. GLDC通过PI3K/Akt/mTOR通路调控卵巢癌细胞的增殖与凋亡[J]. 国际肿瘤学杂志, 2021, 48(12): 716-722.
[8]	关若丹, 摘译. 奥拉帕利对携带BRCA突变的新诊断晚期卵巢癌、原发性腹膜癌、输卵管癌患者维持治疗的有效性研究:SOLO1试验的亚组分析(摘译)[J]. 国际肿瘤学杂志, 2021, 48(12): 764-768.
[9]	郑静, 姚胜, 沈文洁, 孙志佳, 赵辉, 付艳, 高珂, 杜楠. 腹腔灌注贝伐珠单抗联合白蛋白紫杉醇和卡铂治疗卵巢癌所致癌性腹腔粘连的临床探讨[J]. 国际肿瘤学杂志, 2021, 48(11): 660-665.
[10]	杨立芬, 宋伟, 许大伟, 武军, 高然. miR-103a-3p/CHI3L1在卵巢癌细胞增殖和血管拟生中的作用机制[J]. 国际肿瘤学杂志, 2020, 47(6): 333-339.
[11]	薛晨, 赵月, 石光, 唐艳. PD-1/PD-L1抑制剂在卵巢癌中的研究进展[J]. 国际肿瘤学杂志, 2020, 47(5): 312-315.
[12]	杨怡婷, 程忠平. 炎症细胞因子在卵巢上皮癌化疗耐药中的作用[J]. 国际肿瘤学杂志, 2020, 47(4): 249-251.
[13]	樊阳阳, 王影, 袁峰, 杜善平, 贺荣荣, 加燕. MALAT1靶向miR-142-3p在卵巢癌化疗耐药中的机制研究[J]. 国际肿瘤学杂志, 2020, 47(2): 82-89.
[14]	权瑞泉, 张丽, 匡黎, 李洪波, 肖梅仙. 奥拉帕尼联合贝伐珠单抗治疗复发性铂类敏感卵巢癌患者的疗效及对血清HE4、CA125、CTC水平的影响[J]. 国际肿瘤学杂志, 2020, 47(10): 606-610.
[15]	丁宇, 乔贵宾. 液体活检在肺癌早期诊断中的应用[J]. 国际肿瘤学杂志, 2019, 46(9): 548-552.